<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17302079</identifier>
<setSpec>0034-9356</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Fuentes Baena, A</dc:author>
<dc:author>Añez Simón, C</dc:author>
<dc:author>Rodríguez Pérez, A</dc:author>
<dc:author>Rull Bartomeu, M</dc:author>
<dc:description xml:lang="en">Intranasal drug administration is an easy, well-tolerated, noninvasive transmucosal route that avoids first-pass metabolism in the liver. The nasal mucosa provides an extensive, highly vascularized surface of pseudostratified ciliated epithelium. It secretes mucus that is subjected to mucociliary movement that can affect the time of contact between the drug and the surface. Absorption is influenced by anatomical and physiological factors as well as by properties of the drug and the delivery system. We review the literature on intranasal administration of fentanyl, meperidine, diamorphine, and butorphanol to treat acute pain. The adverse systemic effects are similar to those described for intravenous administration, the most common being drowsiness, nausea, and vomiting. Local effects reported are a burning sensation with meperidine and a bad taste.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2006 Dec </dc:date>
<dc:title xml:lang="es">Opioides por vía intranasal en el tratamiento del dolor agudo.</dc:title>
<dc:title xml:lang="en">[Intranasal opioids for acute pain].</dc:title>
<dc:publisher>Revista espanola de anestesiologia y reanimacion</dc:publisher>
</metadata>
</record>
</pubmed-document>
